Recruiting

Observational Study

Sponsor:

Pulmonary Care and Research Collaborative Limited

Code:

NCT05445817

Conditions

Interstitial Lung Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The purpose of this research study is to build and maintain a registry of people with interstitial lung disease (ILD). Medical information collected for this registry may be used to advance ILD and pulmonary research and improve patient care. This is an observational registry. Participants will not receive any investigational treatments or investigational drugs as part of their participation in this registry.

Conditions

Interstitial Lung Disease

Study ID

NCT05445817

Start date

Jul, 2022

Status verified date

Jul, 2022

Completion date

Mar, 2024

Anticipated

Primary completion date

Dec, 2023

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • People with a confirmed diagnosis of interstitial lung disease by a primary care physician and/or pulmonologist.

Exclusion Criteria:

-

Study Design

Enrollment

150 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Development and implementation of a database populated with de-identified longitudinal medical histories of interstitial lung disease patients. [ Time Frame: Up to 18 months ]

Central Contacts and Locations

Central contacts

Aliaa Barakat, PhD

617-895-6636aliaa.barakat@ildcollaborative.org

Arthur Dea, BA

617-895-9879arthur.dea@ildcollaborative.org

Locations

Pulmonary Care and Research Collaborative, Ltd.

Recruiting

Boston, Massachusetts, United States, 02130

Contacts

Aliaa Barakat, PhD

617-895-6636aliaa.barakat@ildcollaborative.org

Arthur Dea, BA

617-895-9879arthur.dea@ildcollaborative.org

Principal Investigator:

Aliaa Barakat, PhD

More Information

Sponsor

Pulmonary Care and Research Collaborative Limited

Last update posted

Jul 19, 2022

Last verified

Jul, 2022

Keywords

  • Progressive Fibrosing Interstitial Lung Disease
  • Idiopathic Pulmonary Fibrosis
  • Interstitial Lung Disease Associated With Systemic Sclerosis
  • Myositis-Associated Interstitial Lung Disease
  • Sarcoidosis
  • Hypersensitivity Pneumonitis
  • Pulmonary Fibrosis

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Pulmonary Care and Research Collaborative Limited on 2022-07-19.